- Conditions
- Hepatitis C
- Interventions
- Glecaprevir/pibrentasvir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 8
- States / cities
- Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Glecaprevir/Pibrentasvir
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Glecaprevir/Pibrentasvir (GLE/PIB)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 37
- States / cities
- Chandler, Arizona • Peoria, Arizona • Little Rock, Arkansas + 31 more
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 15
- States / cities
- San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Glecaprevir/Pibrentasvir
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- San Diego, California • San Francisco, California • West Hollywood, California + 2 more
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Glecaprevir/pibrentasvir
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 11
- States / cities
- La Jolla, California • Pasadena, California • Tampa, Florida + 7 more
- Conditions
- Hepatitis C, HCV
- Interventions
- Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 31
- States / cities
- Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Glecaprevir/Pibrentasvir
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • Sacramento, California + 7 more
- Conditions
- Hepatitis C Virus Infection, Response to Therapy of
- Interventions
- Test and treat plus peer mentors, Usual care
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • San Francisco, California • Baltimore, Maryland
- Conditions
- Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
- Interventions
- glecaprevir/pibrentasvir (GLE/PIB)
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California